Salarius Pharma CEO David J. Arthur resigns; CFO Mark J. Rosenblum named acting CEO

Decoy Therapeutics Inc.

David J. Arthur resigned as CEO effective Aug 17, 2025; not due to any disagreement with the company.
Mark J. Rosenblum appointed acting CEO, continuing as EVP and CFO; no new employment agreement.
Consulting agreement with Arthur terminated immediately upon resignation.
Rosenblum has served as EVP Finance/CFO since Sep 2019; previously CFO of Advaxis, Inc.
Company working to finalize previously announced merger with Decoy Therapeutics Inc.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.